Head-to-head evidence
Idecabtagene vicleucel vs PHE885
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Idecabtagene vicleucel
Marketed by Bristol-Myers Squibb
NCT03651128 · Phase 3 · completed
Randomized, open-label Phase 3 trial (n=386) demonstrating significant improvement in PFS vs standard regimens in relapsed/refractory multiple myeloma (NEJM 2023).
Next expected readout: May 2027 · NCT05393804 (registry estimate)
PHE885
Developed by Novartis
NCT04318327 · Phase 1 · terminated
This is an early-phase, open-label study without randomization, blinding, or a control arm, in which every enrolled patient received the CAR-T therapy; its primary goal was to characterize safety and dose-limiting toxicity rather than to compare efficacy against a control treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Idecabtagene vicleucel's landscape · PHE885's landscape